SCHEMBL6465216

SCHEMBL6465216

O=C(NCC(C(=O)NCCCCCC(=O)c1nc2ccccc2o1)S(=O)(=O)Cc1ccccc1OC(F)F)c1ccncc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.39
DAGLA Q9Y4D2 5/20 0.39
CES1 P23141 2/20 0.39
HDAC6 Q9UBN7 3/20 0.36
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
HDAC3 O15379 3/20 0.33
HDAC1 Q13547 3/20 0.33
HDAC4 P56524 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC11 Q96DB2 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC9 Q9UKV0 1/20 0.33
HDAC5 Q9UQL6 1/20 0.33
CTSS P25774 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6466177 0.90 DAGLA (0.44) FAAHDAGLACES1HDAC6HDAC3
SCHEMBL6063913 0.84 FAAH (0.37) FAAHDAGLACES1HDAC6HDAC3
SCHEMBL7043323 0.84 DAGLA (0.47) FAAHDAGLACES1HDAC6CYP1A2
SCHEMBL6467763 0.83 FAAH (0.36) FAAHDAGLACES1HDAC6HDAC3
SCHEMBL6462832 0.80 DAGLA (0.43) FAAHDAGLACES1HDAC6HDAC3
SCHEMBL7043208 0.80 FAAH (0.41) FAAHDAGLACES1HDAC6HDAC3
SCHEMBL6636292 0.79 DAGLA (0.45) FAAHDAGLACES1HDAC6HDAC3
SCHEMBL6630032 0.78 DAGLA (0.40) FAAHDAGLACES1HDAC6HDAC3
SCHEMBL7048391 0.76 FAAH (0.40) FAAHDAGLACES1HDAC6
SCHEMBL6063780 0.76 FAAH (0.41) FAAHDAGLACES1CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1516877-A1 Amine derivatives as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-03-23 EP claimed
US-20030232864-A1 Novel Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-12-18 US claimed
US-6576630-B1 Alkanoyl substituted benzooxazoles or naphthooxazoles AXYS PHARMACEUTICALS, INC. 2003-06-10 US claimed
EP-1516877-A1 Amine derivatives as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-03-23 EP disclosed
US-20030232864-A1 Novel Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-12-18 US disclosed
US-6576630-B1 Alkanoyl substituted benzooxazoles or naphthooxazoles AXYS PHARMACEUTICALS, INC. 2003-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232864-A1 Novel Compounds and compositions as protease inhibitors SERPINB1, CTRL, CTSZ FAAH 479/4885DAGLA 2304/4885CES1 272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.